Prediction of Gait After Stroke; an External Validation
Launched by KANTONSSPITAL WINTERTHUR KSW · May 27, 2024
Trial Information
Current as of February 18, 2025
Completed
Keywords
ClinConnect Summary
Worldwide, stroke is the second leading cause of death and is also the third leading cause of death and disability combined. According to the Global Burden of Disease, Injuries, and Risk Factors Study (GBD) by the Collaborator Network on the topic of stroke, the absolute number of incidence strokes and their deaths have steadily increased in recent years. The most important risk factors include high blood pressure, a high body-mass index, high plasma glucose, fine dust pollution and smoking. In Switzerland, an average of 20'423 people suffered a stroke per year between 2016 and 2020. Due to...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. aged 18 years or older
- • 2. having suffered an ischemic or hemorrhagic stroke, confirmed by computerized tomography and/ or magnetic resonance imaging
- • 3. being unable to walk independently (FAC \< 4) within 72 hours
- • 4. giving written informed consent to participate
- Exclusion Criteria:
- • 1. not able to walk independently before hospital admission (FAC \< 4)
- • 2. clinically significant comorbidities that prevent walking ability
- • 3. deficits in cognition or communication, so consent cannot be given for study participation
About Kantonsspital Winterthur Ksw
Kantonsspital Winterthur (KSW) is a leading academic hospital located in Winterthur, Switzerland, dedicated to providing high-quality patient care and advancing medical research. As a prominent clinical trial sponsor, KSW engages in innovative studies aimed at improving healthcare outcomes across various medical disciplines. The institution is committed to fostering collaboration between healthcare professionals and researchers, ensuring adherence to rigorous ethical standards and regulatory compliance. With state-of-the-art facilities and a multidisciplinary team of experts, KSW plays a pivotal role in the development of new therapies and treatment protocols that enhance patient care and contribute to the broader scientific community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Winterthur, Zürich, Switzerland
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0